Home › Neuroblastoma › Pennsylvania
Neuroblastoma clinical trials in Pennsylvania
14 studies for Neuroblastoma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Children's Hospital of Philadelphia, Philadelphia
- and 2 more
RecruitingPhase 3
Up to age 30 · All sexes · Updated Oct 2, 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RecruitingPhase 2
Up to age 22 · All sexes · Updated Sep 4, 2026 · NCT02559778Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Sep 3, 2026 · NCT06541262Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RecruitingPhase 2
Ages 1 to 21 · All sexes · Updated Sep 3, 2026 · NCT06540963Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- and 2 more
RecruitingPhase 3
365 Days – 30 Years · All sexes · Updated Aug 25, 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RecruitingPhase 2
12 Months – 21 Years · All sexes · Updated Aug 12, 2026 · NCT05489887SPEARHEAD-3 Pediatric Study
- Children's Hospital of Philedephia, Philadelphia
RecruitingPhase 1/2
Ages 2 to 21 · All sexes · Updated Aug 11, 2026 · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1/2
Ages 1 to 30 · All sexes · Updated Jul 22, 2026 · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 1 to 31 · All sexes · Updated Jul 20, 2026 · NCT06450041Neuroblastoma Biology Study
- Children's Hospital of Philadelphia, Philadelphia
RecruitingObservational study
31 Days – 99 Years · All sexes · Updated Mar 23, 2026 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Children's Hospital of Philadelphia, Philadelphia
Recruiting
Up to age 17 · All sexes · Updated Feb 10, 2026 · NCT06831552From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.